Main content

    ALS / Neuromuscular Disorders
    Clinical Trials

    The Forbes Norris MDA/ALS Research Center

    Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov


    Amyotrophic Lateral Sclerosis (ALS)  |  Neuromuscular Studies


    Active Trials

    Amyotrophic Lateral Sclerosis (ALS)

    Title: A Phase 2A Safety and Biomarker Study of EPI-589 in Subjects With Amyotrophic Lateral Sclerosis
    Description: The purpose of this Phase II research study is to determine safety of EPI-589 and its effects on glutathione in ALS
    Investigator: Jonathan Katz, MD
    Eligibility: Patients with amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig's disease who have had symptoms for less than 3 years and FVC above 70%
    Status: Active and open to enrollment
    Contact: Dallas Forshew, RN, 415-309-5178, Email: ForsheD@cpmcri.org about Study Edison

    Title: A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerability and Efficacy of Tirasemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)
    Description: The purpose of this Phase III research study is to see if the drug Tirasemtiv will improve breathing capacity and muscle strength in People with ALS
    Investigator: Jonathan Katz, MD
    Eligibility: Patients with amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig's disease who have been diagnosed for no more than 2 years
    Status: Active and open to enrollment
    Contact: Marguerite Engel, 415-600-3758, Email: EngelM@cpmcri.org about Study Cytokinetics

    Title: (MDA Registry 1212M25862): Muscular Dystrophy Association U.S. Neuromuscular Disease Registry
    Description: The purpose of this study is to gain insight into disease trends of progression and treatment so as to improve treatment and patient survival. As these neuromuscular diseases become better understood, the quality of care should improve
    Investigator: Jonathan Katz, MD
    Eligibility: 
Subjects with amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig's disease
    Status: Active and open to enrollment

    Contact: Dallas Forshew, RN, 415-309-5178, Email: ForsheD@cpmcri.org about Study MDA Registry 1212M25862

    Title: Multi-center, randomized controlled study of the NeuRx® Diaphragm Pacing System™ in participants with Amyotrophic Lateral Sclerosis (ALS)
    Description: The purpose of this study is to see whether electrical stimulation of the diaphragm (the main breathing muscle at the bottom of your chest) with the NeuRx® Diaphragm Pacing System™ benefits people with ALS
    Investigator: Jonathan Katz, MD
    Eligibility: 
Subjects with amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig's disease who have moderate diaphragm weakness
    Status: Active and open to enrollment

    Contact: Dallas Forshew, RN, 415-309-5178, Email: ForsheD@cpmcri.org about Study NeuRx DPS Randomized Controlled Trial

    Title: HDE Post-Approval Study (PAS) of NeuRx DPS TM (Diaphragm Pacing System) for ALS
    Description: The purpose of this research study is to collect more information about the possible risks and benefits of the NeuRx DPS TM device (Diaphragm Pacing System)
    Investigator: Jonathan Katz, MD
    Eligibility: Subjects with amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig's disease who have moderate diaphragm weakness
    Status: Active and open to enrollment
    Contact: Dallas Forshew, RN, 415-309-5178, Email: ForsheD@cpmcri.org about Study NeuRx DPS

    Back to top

    Neuromuscular Studies

    Title: (IGOS): A Prospective INC Study on Clinical and Biological Predictors of Disease Course and Outcome in GBS
    Description: The purpose of this study is to help researchers learn more about the clinical and biological factors that influence the course of GBS, the outcome of patients with GBS, and to find factors that could help diagnose GBS sooner
    Investigator: Jonathan Katz, MD
    Eligibility: Patients with Guillain-Barré Syndrome (GBS) who have not yet received treatment for GBS
    Status: Active and open to enrollment
    Contact: Dallas Forshew, RN, 415-309-5178, Email: ForsheD@cpmcri.org about Study IGOS

    Title: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Eculizumab in Subjects With Refractory Generalized Myasthenia Gravis (gMG)
    Description: The purpose of this study is to determine if eculizumab is safe and effective for the treatment of patients with refractory gMG
    Investigator: Jonathan Katz, MD
    Eligibility: Subjects with generalized myasthenia gravis (gMG) who have needed at least two immunosuppressive drugs, or one immunosuppressive drug and regular plasma exchange or IVIG to control symptoms

    Status: Active and closed to enrollment

    Contact: Marguerite Engel, 415-600-3758, Email: EngelM@cpmcri.org about Study Refractory MG

    Title: Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS)
    Description: The purpose of this study is to test four different drugs to see which might work best for the symptoms of cryptogenic sensory polyneuropathy
    Investigator: Jonathan Katz, MD
    Eligibility: Patients with painful neuropathy for which the cause is unknown. This is called cryptogenic sensory polyneuropathy (CSPN)
    Status: Active and open to enrollment

    Contact: Marguerite Engel, 415-600-3758, Email: EngelM@cpmcri.org about Study PAIN-CONTRoLS

    • updated January 2016

    Back to top